NeuroSeriesLive

CME Presentations

Chronic Inflammatory Demyelinating Polyneuropathy


Presentations


Speakers

  • Richard J. Barohn, MD

    Richard J. Barohn, MD

    Richard J. Barohn, MD

    Gertrude and Dewey Ziegler Professor of Neurology

    Richard J. Barohn, MD, is the vice chancellor for research, a University Distinguished Professor, and the Gertrude and Dewy Ziegler Professor, Department of Neurology, at the University of Kansas Medical Center (KU Medical Center) in Kansas City. His research focuses on myopathies (such as polymyositis and muscular dystrophy), motor neuron diseases (such as amyotrophic lateral sclerosis), peripheral neuropathies and myasthenia gravis. Dr Barohn is the principal investigator on the National Institutes of Health Clinical and Translational Science Award and the NeuroNEXT grant at KU Medical Center, and is Director of Frontiers: The University of Kansas Clinical and Translational Research Institute. He earned his medical degree from the University of Missouri-Kansas City School of Medicine.
  • Roy L. Freeman, MD

    Roy L. Freeman, MD

    Roy L. Freeman, MD

    Professor of Neurology

    Roy Freeman, MD, is a professor of neurology at Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr Freeman’s research encompasses the neurological complications of diabetes and other peripheral neuropathies, neuropathic pain, the autonomic complications of Parkinson’s disease and multiple system atrophy, biomarkers in neurodegenerative diseases, and the diagnosis and treatment of autonomic and peripheral nervous system disorders. He is the principal investigator on National Institutes of Health-funded studies on the neurological complications of diabetes and biomarker development in alpha-synucleinopathies.
  • Jonathan Katz, MD

    Jonathan Katz, MD

    Jonathan Katz, MD

    Adjunct Professor of Neurology

    Jonathan S. Katz, MD, is the director of the Forbes Norris MDA/ALS Research & Treatment Center at California Pacific Medical Center in San Francisco, as well as s an adjunct professor of neurology at the University of Kansas School of Medicine in Kansas City. His professional interests include amyotrophic lateral sclerosis, electromyography, motor neuron diseases, myasthenia gravis, neuromuscular disease, neuropathy testing, pain management, peripheral neuropathy, poliomyelitis - late effect, radiculopathies, and spinal muscular atrophy. Dr Katz has published extensively in the inflammatory neuropathies, use of IVIg, and in the area of amyotrophic lateral sclerosis. He earned his medical degree from Tulane University School of Medicine in New Orleans, Louisiana.

CME Information

Case–Based Approach to the Differential Diagnosis, Treatment, and Long–Term Follow–up of CIDP


LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Formulate a differential diagnosis for a patient who exhibits signs and symptoms of CIDP
  • Comparatively assess the safety and efficacy of first-line treatment options for CIDP
  • Recognize clinical and neurophysiological parameters of treatment outcomes that indicate stability, improvement, or disease progression
  • Identify when and how to modify therapy over the course of the disease

Acknowledgement

This activity is supported by educational grants from CSL Behring LLC and Grifols.

Tuition

Complimentary

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

Live Internet Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release/Expiration

Live Activity

Thursday, May 31, 2018 from 12:00pm – 1:00pm EDT.

Enduring Material

The enduring material will be available from May 31, 2018 to July 11, 2019.

Target Audience

This activity is intended for US-based neurologists, immunologists, internal medicine physicians, physician assistants, nurse practitioners, and nurses who manage, or have an interest in managing, patients with immune-mediated neuropathies.

Method Of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Facutly

Roy Freeman, MD, MB, ChB
Professor of Neurology
Harvard Medical School
Director, Center for Autonomic and Peripheral Nerve Disorders
Beth Israel Deaconess Medical Center

Richard J. Barohn, MD
Gertrude and Dewey Ziegler Professor of Neurology
University Distinguished Professor
Vice Chancellor for Research
President of the Research Institute
University of Kansas Medical Center

Jonathan Katz, MD
Director
Forbes Norris Center for Neuromuscular Disorders
Adjunct Professor of Neurology
Kansas University School of Medicine

Faculty Disclosures

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Reported Financial Relationship

Faculty

  • Roy Freeman, MD, MB, ChB
    None
  • Richard J. Barohn, MD
    Consluting Fees: NuFactor
    Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Option Care, Plan 365 Inc.
    Contracted Research: Alexion, ALSA, BioMarin, Cytokinetics, Eli Lilly, FDA/OOPD, Ionis, Neuraltus, NIH, Novartis, PTC Therapeutics, Sanofi/Genzyme, Sarepta, Teva
  • Jonathan Katz, MD
    Consulting Fees: Alexion, MTP, Grifols, CLS

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Planners

  • Anne Roc, PhD
    Medical Director
    PlatformQ Health Education, LLC
    None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE

(if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroCareLive at 877-394-1306 or at Support@NeuroCareLive.com.